PharmaCyte Biotech Inc (PMCB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.77M
Last updated: Nov 17, 2026 at 4:10 PM ET
PharmaCyte Biotech Inc (PMCB) Stock Chart
PharmaCyte Biotech (PMCB) has a latest price of $5.38 on Nov 17, 2026, 81.2% below its 52-week high of $28.69. Its price fell 64.0% over the past 12 months. The month-end price fell 99.5% over the 10 years through Oct 2026, a compound annual decline of 41.2%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $4,718.00 in Dec 2016 and its lowest $5.74 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart PMCB with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for PMCB.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 46.8%, and over 6 months it fell 61.3%. The month-end price fell 85.8% over the 3 years through Oct 2026, a compound annual decline of 47.8%.
| Period | Change |
|---|---|
| 1 month | -17.2% |
| 3 months | -46.8% |
| 6 months | -61.3% |
| 12 months | -64.0% |
| 12 months, with dividends | -64.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -85.8% | -47.8% |
| 5 years | -89.3% | -36.0% |
| 10 years | -99.5% | -41.2% |
Price by Year
Its best calendar year was 2022, when the price rose 17.2%, and its weakest was 2020, when it fell 83.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $5.74 | -58.3% |
| 2025 | $13.76 | -53.9% |
| 2024 | $29.85 | -27.3% |
| 2023 | $41.06 | -26.3% |
| 2022 | $55.70 | +17.2% |
| 2021 | $47.53 | -77.6% |
| 2020 | $212.29 | -83.5% |
| 2019 | $1,283.27 | +9.5% |
| 2018 | $1,172.37 | -38.3% |
| 2017 | $1,901.14 | -59.7% |
Trading Range
The price is 26.3% below its 50-day average of $7.30 and 53.8% below its 200-day average of $11.64.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $5.38 | |
| 52-week high | $28.69 | -81.2% |
| 52-week low | $4.69 | +14.7% |
| 50-day average | $7.30 | -26.3% |
| 200-day average | $11.64 | -53.8% |
Price Risk
Over 3 years, its largest fall from a peak was 88.8%.
| Measure | Value |
|---|---|
| 1-year beta | 1.93 |
| Largest fall, 1 year | -76.8% |
| Largest fall, 3 years | -88.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About PMCB
What is PMCB's 1-year price change?
PharmaCyte Biotech's price fell 64.0% over the past 12 months. With dividends included, the 12-month total return was -64.0%.
What is PMCB's 5-year price change?
PharmaCyte Biotech's month-end price fell 89.3% over the 5 years through Oct 2026, a compound annual decline of 36.0%. These figures leave out dividends.
What is PMCB's 52-week high and low?
PharmaCyte Biotech's 52-week high is $28.69 and its 52-week low is $4.69. Its latest price of $5.38 on Nov 17, 2026 is 81.2% below the high.
What is PMCB's beta?
PharmaCyte Biotech's 1-year beta against the S&P 500 is 1.93, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 76.8%.
Is the PMCB chart free?
Yes. Advanced Charting for PMCB is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
PMCB pages: Overview, Charting, Earnings, Financials, Statistics, Competitors